Scilex Holding (SCLXW) Asset Writedowns and Impairment (2024)
Scilex Holding (SCLXW) recorded quarterly Asset Writedowns and Impairment of $14.8 million in Q4 2024, up 1183.32% quarter-over-quarter from $1.2 million in Q2 2024.
Scilex Holding (SCLXW) Asset Writedowns and Impairment (2024) Analysis & Trends
Scilex Holding's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $14.8 million for Q4 2024.
- In Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $14.8 million; the TTM figure through Dec 2024 stood at $17.3 million (changed N/A YoY), while the FY2024 annual figure was $17.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $14.8 million for Q4 2024 at Scilex Holding, up from $1.2 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $14.8 million in Q4 2024 to a low of $1.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14.77 Mn |
| Dec 31, 2024 | 14.77 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |